The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Open accessAbstract
Purpose: This phase I dose-escalation study investigated the maximum-tolerated dose (MTD), safety, preliminary activity, pharmacokinetics (PK), and pharmacodynamics of BKM120, a potent and highly specific oral pan-Class I PI3K inhibitor. Patients and Methods: Thirty-five patients with advanced solid tumors received daily BKM120 12.5 to 150 mg. Dose escalation was guided by a Bayesian logistic regression model with overdose control. Assessments included archival tumor molecular status, response by Response Evaluation Criteria in Solid Tumors (RECIST), positron emission tomography tracer uptake ([18 F]fluorodeoxyglucose positron emission tomography [FDG-PET]), fasting plasma C-peptide, and phosphorylated ribosomal protein S6 (pS6) in skin biopsies. Results: Overall, treatment was well tolerated. Dose-limiting toxicities were grade 2 mood alteration (80 mg), grade 3 epigastralgia, grade 3 rash, grade 2 and grade 3 mood alteration (100 mg), and two grade 4 hyperglycemia (150 mg). The MTD was 100 mg/d. Frequent treatment-related adverse events included rash, hyperglycemia, diarrhea, anorexia, and mood alteration (37% each); nausea (31%); fatigue (26%); pruritus (23%); and mucositis (23%). BKM120 demonstrated rapid absorption, half-life of ∼40 hours, ∼three-fold steady-state accumulation, dose-proportional exposure, and moderate interpatient variability. One patient demonstrated a confirmed partial response (triple-negative breast cancer); seven patients (20%) were on study for ≥ 8 months. BKM120 demonstrated dose-dependent pharmacodynamic effects on [18 F]FDG-PET, fasting C-peptide, fasting blood glucose, and pS6. No significant trends were seen to correlate tumor molecular alterations with clinical activity. Conclusion: This study demonstrates feasibility and proof-of-concept of class I PI3K inhibition in patients with advanced cancers. BKM120, at the MTD of 100 mg/d, is safe and well tolerated, with a favorable PK profile, clear evidence of target inhibition, and preliminary antitumor activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Self-citationThe phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Critical nodes in signalling pathways: insights into insulin action
Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1837 · Cited by 2,760
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,720
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Cited by
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
“The BELLE series of clinical trials assessed the efficacy and safety of various drug combinations with the pan-PI3K inhibitor buparlisib (BKM120; Table S1) in patients with ER+, HER2– breast cancer.”
BackgroundTargeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,892
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
CNS Metastases in Breast Cancer: Old Challenge, New Frontiers
Lin, N. U., Amiri-Kordestani, L., Palmieri, D., Liewehr, D. J., & Steeg, P. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0790 · Cited by 1,286
Imaging biomarker roadmap for cancer studies
O'Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., Boellaard, R., Bohndiek, S. E., Brady, M., Brown, G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.162 · Cited by 1,091
Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Schmitz, R., Young, R. M., Ceribelli, M., Jhavar, S., Xiao, W., Zhang, M., Wright, G., Shaffer, A. L., Hodson, D. J., Buras, E., et al. (2012) · Nature · doi:10.1038/nature11378 · Cited by 924
Depression and anxiety in patients with cancer
Pitman, A., Suleman, S., Hyde, N., & Hodgkiss, A. (2018) · BMJ · doi:10.1136/bmj.k1415 · Cited by 871
The PI3K/AKT Pathway as a Target for Cancer Treatment
Mayer, I. A., & Arteaga, C. L. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-062913-051343 · Cited by 822
Development of PI3K inhibitors: lessons learned from early clinical trials
Rodon, J., Dienstmann, R., Serra, V., & Tabernero, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.10 · Cited by 766
Self-citationMolecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Polivka, J., & Janku, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.004 · Cited by 765
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Hopkins, B. D., Pauli, C., Du, X., Wang, D. G., Li, X., Wu, D., Amadiume, S. C., Goncalves, M. D., Hodakoski, C., Lundquist, M. R., et al. (2018) · Nature · doi:10.1038/s41586-018-0343-4 · Cited by 706
Tewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.008 · Cited by 642
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Paplomata, E., & O’Regan, R. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014530023 · Cited by 593
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Li, X., Wu, C., Chen, N., Gu, H., Yen, A., Cao, L., Wang, E., & Wang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7961 · Cited by 542
Fritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D., Erdmann, D., De Pover, A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 501
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
Gajria, D., & Chandarlapaty, S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.226 · Cited by 494
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer
Fumarola, C., Bonelli, M. A., Petronini, P. G., & Alfieri, R. R. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.05.011 · Cited by 463
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Dienstmann, R., Rodon, J., Serra, V., & Tabernero, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0639 · Cited by 462
Self-citationCDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438
“Laboratory studies and these early clinical trials indicate that several of the PI3K inhibitors (PI3Ki) demonstrate preferential inhibition of tumors with PIK3CA mutations (Bendell et al., 2012; O’Brien et al., 2010).”
Limits to Personalized Cancer Medicine
Tannock, I. F., & Hickman, J. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmsb1607705 · Cited by 415
Obesity and Cancer Mechanisms: Cancer Metabolism
Hopkins, B. D., Goncalves, M. D., & Cantley, L. C. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9712 · Cited by 414
Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
Miller, T. W., Balko, J. M., & Arteaga, C. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4879 · Cited by 413
The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
Slomovitz, B. M., & Coleman, R. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0662 · Cited by 397
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
Dreyling, M., Santoro, A., Mollica, L., Leppä, S., Follows, G. A., Lenz, G., Kim, W. S., Nagler, A., Panayiotidis, P., Demeter, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.4648 · Cited by 395
Tenbaum, S. P., Ordóñez-Morán, P., Puig, I., Chicote, I., Arqués, O., Landolfi, S., Fernández, Y., Herance, J. R., Gispert, J. D., Mendizabal, L., et al. (2012) · Nature Medicine · doi:10.1038/nm.2772 · Cited by 386
Self-citationTargeting RTK Signaling Pathways in Cancer
Regad, T. (2015) · Cancers · doi:10.3390/cancers7030860 · Cited by 380
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
Saini, K. S., Loi, S., de Azambuja, E., Metzger-Filho, O., Saini, M. L., Ignatiadis, M., Dancey, J. E., & Piccart-Gebhart, M. J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.03.009 · Cited by 374
Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
Markman, B., Dienstmann, R., & Tabernero, J. (2010) · Oncotarget · doi:10.18632/oncotarget.188 · Cited by 355
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies
Lee, A., & Djamgoz, M. B. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.003 · Cited by 354
Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005747 · Cited by 332
Self-citationUnderstanding, recognizing, and managing toxicities of targeted anticancer therapies
Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21184 · Cited by 331
Bedard, P. L., Tabernero, J., Janku, F., Wainberg, Z. A., Paz-Ares, L., Vansteenkiste, J., Van Cutsem, E., Pérez-García, J., Stathis, A., Britten, C. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1814 · Cited by 324
Self-citationMayer, I. A., Abramson, V. G., Formisano, L., Balko, J. M., Estrada, M. V., Sanders, M. E., Juric, D., Solit, D., Berger, M. F., Won, H. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0134 · Cited by 319
Precision medicine for metastatic breast cancer—limitations and solutions
Arnedos, M., Vicier, C., Loi, S., Lefebvre, C., Michiels, S., Bonnefoi, H., & Andre, F. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.123 · Cited by 317
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Franklin, R. A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.659 · Cited by 314
Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
Matter, M. S., Decaens, T., Andersen, J. B., & Thorgeirsson, S. S. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.031 · Cited by 314
Sarker, D., Ang, J. E., Baird, R., Kristeleit, R., Shah, K., Moreno, V., Clarke, P. A., Raynaud, F. I., Levy, G., Ware, J. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0947 · Cited by 313
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
Bitting, R. L., & Armstrong, A. J. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-12-0394 · Cited by 311
Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood
Higgins, M. J., Jelovac, D., Barnathan, E., Blair, B., Slater, S., Powers, P., Zorzi, J., Jeter, S. C., Oliver, G. R., Fetting, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2696 · Cited by 309
Current approaches to the treatment of metastatic brain tumours
Owonikoko, T. K., Arbiser, J., Zelnak, A., Shu, H.-K. G., Shim, H., Robin, A. M., Kalkanis, S. N., Whitsett, T. G., Salhia, B., Tran, N. L., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.25 · Cited by 304
Insulin–PI3K signalling: an evolutionarily insulated metabolic driver of cancer
Hopkins, B. D., Goncalves, M. D., & Cantley, L. C. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0329-9 · Cited by 288
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Mishra, R., Patel, H., Alanazi, S., Kilroy, M. K., & Garrett, J. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073464 · Cited by 281
PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
Hsieh, A., & Edlind, M. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122876 · Cited by 276
HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma
Pei, Y., Liu, K.-W., Wang, J., Garancher, A., Tao, R., Esparza, L. A., Maier, D. L., Udaka, Y. T., Murad, N., Morrissy, S., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.011 · Cited by 276
PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer
Marquard, F. E., & Jücker, M. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113729 · Cited by 270
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
Akinleye, A., Avvaru, P., Furqan, M., Song, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-88 · Cited by 254
The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis
Woodcock, H. V., Eley, J. D., Guillotin, D., Platé, M., Nanthakumar, C. B., Martufi, M., Peace, S., Joberty, G., Poeckel, D., Good, R. B., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07858-8 · Cited by 224
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
Turner, N. C., Neven, P., Loibl, S., & Andre, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32419-9 · Cited by 205
Hanker, A. B., Pfefferle, A. D., Balko, J. M., Kuba, M. G., Young, C. D., Sánchez, V., Sutton, C. R., Cheng, H., Perou, C. M., Zhao, J. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303204110 · Cited by 203
“We next determined whether these tumors responded to BKM120, which has currently completed phase I studies in patients with cancer (23).”
BackgroundPI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
Leiphrakpam, P., & Are, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063178 · Cited by 193
Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape
Salvadori, G., Zanardi, F., Iannelli, F., Lobefaro, R., Vernieri, C., & Longo, V. D. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.10.008 · Cited by 159
Shapiro, G. I., Rodon, J., Bedell, C., Kwak, E. L., Baselga, J., Braña, I., Pandya, S. S., Scheffold, C., Laird, A. D., Nguyen, L. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1777 · Cited by 152
Self-citationScheffler, M., Bos, M., Gardizi, M., König, K., Michels, S., Fassunke, J., Heydt, C., Künstlinger, H., Ihle, M., Ueckeroth, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2834 · Cited by 147
“Up to now, PI3Kinhibitors have not yet proven to be clinically effective, at least in lung cancer, in the majority of patients with PIK3CA-mutation [7, 22, 26].”
BackgroundManagement of toxicity to isoform α-specific PI3K inhibitors
Nunnery, S. E., & Mayer, I. A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz440 · Cited by 137
Sai, J., Owens, P., Novitskiy, S. V., Hawkins, O. E., Vilgelm, A. E., Yang, J., Sobolik, T., Lavender, N., Johnson, A. C., McClain, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2142 · Cited by 138
The role of the PI3K pathway in colorectal cancer
Papadatos-Pastos, D., Rabbie, R., Ross, P., & Sarker, D. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.12.006 · Cited by 126
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
Sirico, M., D’Angelo, A., Gianni, C., Casadei, C., Merloni, F., & De Giorgi, U. (2023) · Cancers · doi:10.3390/cancers15030703 · Cited by 121
Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism
Foukas, L. C., Bilanges, B., Bettedi, L., Pearce, W., Ali, K., Sancho, S., Withers, D. J., & Vanhaesebroeck, B. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201953 · Cited by 91
Li, Y., Xu, C., Wang, B., Xu, F., Ma, F., Qu, Y., Jiang, D., Li, K., Feng, J., Tian, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33282-0 · Cited by 80
AKT is a therapeutic target in myeloproliferative neoplasms
Khan, I., Huang, Z., Wen, Q., Stankiewicz, M. J., Gilles, L., Goldenson, B., Schultz, R., Diebold, L., Gurbuxani, S., Finke, C. M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.167 · Cited by 74
Tan, D. S. W., Camilleri‐Broët, S., Tan, E. H., Alifano, M., Lim, W., Bobbio, A., Zhang, S., Ng, Q., Ang, M., Iyer, N. G., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28750 · Cited by 43
Bowles, D. W., Kochenderfer, M., Cohn, A., Sideris, L., Nguyen, N., Cline-Burkhardt, V., Schnadig, I., Choi, M., Nabell, L., Chaudhry, A., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.03.004 · Cited by 42
Targeting the PI 3K signaling pathway in KRAS mutant colon cancer
Hong, S., Kim, S., Kim, H. Y., Kang, M., Jang, H. H., & Lee, W. (2016) · Cancer Medicine · doi:10.1002/cam4.591 · Cited by 37
Zhang, X., Birtwistle, M., & Gallo, J. (2014) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.65 · Cited by 33
Li, X., Martinez-Ledesma, E., Zhang, C., Gao, F., Zheng, S., Ding, J., Wu, S., Nguyen, N., Clifford, S. C., Wen, P. Y., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0325 · Cited by 27
Algazi, A. P., Rotow, J., Posch, C., Ortiz‐Urda, S., Pelayo, A., Munster, P. N., & Daud, A. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12777 · Cited by 23
Cheung, Y.-M. M., McDonnell, M., & Hamnvik, O.-P. R. (2022) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100776 · Cited by 21
Metadata
- Authors
- Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., Goldbrunner, M., & Baselga, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-01-20
- Volume
- 30
- Issue
- 3
- Pages
- 282-290
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2165404212
- Cited by
- 684
- References
- 37
- FWCI
- 25.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.